Identification of a novel class of orally active pyrimido[5,4-3][1,2,4] triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 17, 2003, Pages 2895-2898

  Guertin, Kevin R ^a   Setti, Lina ^a   Qi, Lida ^a   Dunsdon, Rachel M ^a   Dymock, Brian W ^a   Jones, Philip S ^a   Overton, Hilary ^a   Taylor, Mathew ^a   Williams, Glyn ^a   Sergi, Joseph A ^a   Wang, Karen ^a   Peng, Ying ^a   Renzetti, Marcia ^a   Boyce, Rogely ^a   Falcioni, Fiorenza ^a   Garippa, Ralph ^a   Olivier, Andrée R ^a  

^a HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DIAMINE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG IDENTIFICATION; ENZYME ACTIVITY; ENZYME INHIBITION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN;

EID: 10744220924     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00623-1     Document Type: Article

References (28)

1. Defronzo R.A. Diabet. Rev. 5:1997;177.
2. Klein R. Diabetes Care. 18:1995;258.
3. Neel B.G., Tonks N.K. Curr. Opin. Cell Biol. 9:1997;93.
4. (c) Ahmad F., Goldstein B.J. Biochim. Biophys. Acta. 1248:1995;57.
5. (b) Goldstein B.J. Receptor. 3:1993;1
6. (b) Goldstein B.J. Receptor. 3:1993;1
7. (a) Goldstein B.J. J. Cell. Biochem. 31:1992;33 (b) Goldstein B.J. Receptor. 3:1993;1 (c) Ahmad F., Goldstein B.J. Biochim. Biophys. Acta. 1248:1995;57.
8. Byon J.C.H., Kusari A.B., Kusari J. Mol. Cell. Biochem. 182:1998;101.
9. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M., Kennedy B.P. Science. 283:1999;1544.
10. (a) Huyer G., Liu S., Kelly J. J. Biol. Chem. 272:1997;843
11. (b) Tsiani E., Fantus G. Trends Endocrinol. Metab. 8:1997;51
12. (c) Posner B.I., Faure R., Burgess J.W., Bevan A.P., Lachance D., Zhang-Sun G., Fantus I.G., Ng J.B., Hall D.A., Lum B.S. J. Biol. Chem. 269:1994;4596
13. (d) Yale J.F., Lachance D., Bevan A.P., Vigeant C., Shaver A., Posner B.I. Diabetes. 44:1995;1274
14. (e) Halberstan M., Cohen N., Shlimovich P., Rosetti L., Shamoon H. Diabetes. 45:1996;659
15. (a) Huyer G., Liu S., Kelly J. J. Biol. Chem. 272:1997;843 (b) Tsiani E., Fantus G. Trends Endocrinol. Metab. 8:1997;51 (c) Posner B.I., Faure R., Burgess J.W., Bevan A.P., Lachance D., Zhang-Sun G., Fantus I.G., Ng J.B., Hall D.A., Lum B.S. J. Biol. Chem. 269:1994;4596 (d) Yale J.F., Lachance D., Bevan A.P., Vigeant C., Shaver A., Posner B.I. Diabetes. 44:1995;1274 (e) Halberstan M., Cohen N., Shlimovich P., Rosetti L., Shamoon H. Diabetes. 45:1996;659 (f) Fantus I.G., Tsiani E. Mol. Cell. Biochem. 182:1998;109.
16. Leung K.W.K., Posner B.I., Just G. Bioorg. Med. Chem. Lett. 9:1999;353.
17. 3CN gradient, lyophilized and isolated as their trifluoroacetate salts.
18. m for each enzyme and 37.5 mM diethylglutarate pH 6.2 was used in place of MES. The reaction was stopped with KOH and the fluorescence of the dephosphorylated substrate measured (excitation: 360 nM/emission: 460 nM).
19. (a) Shaver A., Ng J.B., Hall D.A., Soo Lum B., Posner B.I. Inorg. Chem. 32:1993;3109
20. (a) Shaver A., Ng J.B., Hall D.A., Soo Lum B., Posner B.I. Inorg. Chem. 32:1993;3109 (b) Huyer G., Liu S., Kelly J., Moffat J., Payette P., Kennedy B., Tsaprailis G., Gresser M.J., Ramachandran C. J. Biol. Chem. 272:1997;843.
21. 6, two NH protons could be detected at 6.93 and 8.73 ppm. Mass spectrometry revealed a species whose mass is 2 units higher than parent 16, corresponding to the addition of hydrogen and consistent with the structure 17.
22. Mahadev K., Zilbering A., Zhu L., Goldstein B. J. J. Biol. Chem. 276:2001;21938.
23. Olivier, A. R. Unpublished results. A detailed account of this work will be published separately.
24. a) Fischer E.H., Charbonneau H., Tonks N.K. Science. 253:1991;401
25. (a) Fischer E.H., Charbonneau H., Tonks N.K. Science. 253:1991;401 (b) Pot D.A., Dixon J.E. Biochim. Biophys. Acta. 1136:1992;35.
26. Coleman D.L. Diabetologia. 14:1978;141.
27. As determined by C, H, N, O, F combustion analysis, the trifluoroacetate salt of compounds 12 and 13 contains 3 mol of TFA per mol of parent 12 and 13. Thus a 50-mg/kg dose of 12 corresponds to 28 mg/kg of parent drug.
28. Preliminary toxicological data was obtained following the 5 day dosing study in ob/ob mice (Table 3). No significant adverse treatment related effects were observed on organ weights, hematological parameters or serum chemistries. A histopathological evaluation of selected tissues was performed and no treatment related microscopic changes were observed.